Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care

Wyeth

Status: Completed

Conditions: Acute Myeloid Leukemia

Treatments: Drug: Mylotarg

Study type: Observational

Funder types: Industry

Identifiers

NCT00161668

0903X-100847

Details and patient eligibility

About

This study is designed to assess the safety of Mylotarg therapy in routine practice.

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Treated by Mylotarg
• Provide ICF